Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Ozempic maker Novo Nordisk on Wednesday said data showed its ... Novo, along with another diabetes leader, Eli Lilly, enjoys ...
MarketWatch1mon
Novo Nordisk’s 27% drop on Friday was a market overreaction, analysts say
Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema ...
KRDO1mon
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
(CNN) — Since Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes, drugmakers Novo Nordisk and Eli Lilly have been battling to leapfrog each other with newer and more ...